Back

Safety and efficacy of anticoagulation for atrial fibrillation in cirrhotic patients

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation stroke prevention with oral anticoagulants in difficult cases Oral Anticoagulation ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Justin Song

David Geffen School of Medicine at UCLA, Los Angeles (United States of America)

7 More presentations in this session

Presentation thumbnail
Anticoagulation-associated bleeding in patients randomised to screening for atrial fibrillation or usual care
Doctor E. Kongebro (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year follow-up of more than 13,000 patients from the ETNA-AF-Europe study
Professor R. De Caterina (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Anticoagulation therapy in patients with atrial fibrillation and active cancer
Doctor J. Jaakkola (Turku, FI)
Abstract Slides Video
Presentation thumbnail
Individual risk prediction of anticoagulation in atrial fibrillation patients with cirrhosis
Assistant Professor I. Kim (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Impact of oral anticoagulants in frail atrial fibrillation patients: a report from an observational registry of european patients
Associate Professor M. Proietti (Milan, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation stroke prevention with oral anticoagulants in difficult cases

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on stroke prevention in atrial fibrillation
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - pro
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources